These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 22323598)

  • 1. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.
    Magro M; Mas V; Chappell K; Vázquez M; Cano O; Luque D; Terrón MC; Melero JA; Palomo C
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3089-94. PubMed ID: 22323598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.
    Palomo C; Mas V; Thom M; Vázquez M; Cano O; Terrón MC; Luque D; Taylor G; Melero JA
    J Virol; 2016 Jun; 90(11):5485-5498. PubMed ID: 27009962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein.
    Xun G; Song X; Hu J; Zhang H; Liu L; Zhang Z; Gong R
    J Virol; 2021 Aug; 95(18):e0048521. PubMed ID: 34160257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.
    Corti D; Bianchi S; Vanzetta F; Minola A; Perez L; Agatic G; Guarino B; Silacci C; Marcandalli J; Marsland BJ; Piralla A; Percivalle E; Sallusto F; Baldanti F; Lanzavecchia A
    Nature; 2013 Sep; 501(7467):439-43. PubMed ID: 23955151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
    Swanson KA; Settembre EC; Shaw CA; Dey AK; Rappuoli R; Mandl CW; Dormitzer PR; Carfi A
    Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9619-24. PubMed ID: 21586636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Potential of Prefusion RSV F-specific Antibodies.
    Rossey I; McLellan JS; Saelens X; Schepens B
    Trends Microbiol; 2018 Mar; 26(3):209-219. PubMed ID: 29054341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.
    Flynn JA; Durr E; Swoyer R; Cejas PJ; Horton MS; Galli JD; Cosmi SA; Espeseth AS; Bett AJ; Zhang L
    PLoS One; 2016; 11(10):e0164789. PubMed ID: 27764150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyclonal and monoclonal antibodies specific for the six-helix bundle of the human respiratory syncytial virus fusion glycoprotein as probes of the protein post-fusion conformation.
    Palomo C; Mas V; Vázquez M; Cano O; Luque D; Terrón MC; Calder LJ; Melero JA
    Virology; 2014 Jul; 460-461():119-27. PubMed ID: 25010277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HRSV prefusion-F protein with Adju-Phos adjuvant induces long-lasting Th2-biased immunity in mice.
    Li H; Ren H; Zhou Y; Zhang Y; Cao L; Xu W
    PLoS One; 2022; 17(1):e0262231. PubMed ID: 35100303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation.
    Más V; Rodriguez L; Olmedillas E; Cano O; Palomo C; Terrón MC; Luque D; Melero JA; McLellan JS
    PLoS Pathog; 2016 Sep; 12(9):e1005859. PubMed ID: 27611367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.
    Blais N; Gagné M; Hamuro Y; Rheault P; Boyer M; Steff AM; Baudoux G; Dewar V; Demers J; Ruelle JL; Martin D
    J Virol; 2017 Jul; 91(13):. PubMed ID: 28404847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
    Mousa JJ; Sauer MF; Sevy AM; Finn JA; Bates JT; Alvarado G; King HG; Loerinc LB; Fong RH; Doranz BJ; Correia BE; Kalyuzhniy O; Wen X; Jardetzky TS; Schief WR; Ohi MD; Meiler J; Crowe JE
    Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6849-E6858. PubMed ID: 27791117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities.
    Sastre P; Melero JA; García-Barreno B; Palomo C
    Vaccine; 2004 Dec; 23(4):435-43. PubMed ID: 15530691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal vaccination with a recombinant protein CTA1-DD-RBF protects mice against hRSV infection.
    Li H; Ren H; Zhang Y; Cao L; Xu W
    Sci Rep; 2021 Sep; 11(1):18641. PubMed ID: 34545126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus.
    Liu C; Day ND; Branigan PJ; Gutshall LL; Sarisky RT; Del Vecchio AM
    Virol J; 2007 Jul; 4():71. PubMed ID: 17623075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.